Savara, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Savara, Inc. - overview
Established
2007
Location
Langhorne, PA, US
Primary Industry
Biotechnology
About
Based in Pennsylvania, US, and founded in 2007, Savara Inc. , a. k. a.
Savara operates as a biotechnology company that focuses on the development of rare respiratory disease therapeutics through the approval and commercialization of advanced medicines. In July 2023, Savara, Inc. raised USD 80 million in PIPE funding from TCG Crossover Management, Frazier Healthcare Partners, and Janus Henderson Investors, with participation from Adage Capital Management, Bain Capital Life Sciences, New Enterprise Associates, and Venrock. The company is publicly listed on Nasdaq under the ticker symbol SVRA.
As of November 2024, Matt Pauls is the CEO of the company. Savara's primary product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF). Currently in Phase 3 clinical development, molgramostim targets autoimmune pulmonary alveolar proteinosis (aPAP), a rare lung condition characterized by impaired surfactant clearance in the alveoli. The treatment is designed to address the underlying immune deficiency in aPAP by enhancing alveolar macrophage function.
Molgramostim represents a potential breakthrough for patients with limited therapeutic options, offering a targeted and non-invasive approach. Savara continues to advance molgramostim through clinical trials, aiming to provide a solution for this challenging and underdiagnosed respiratory condition.
Current Investors
Keiretsu Forum, Bain Capital Life Sciences, Silicon Valley Bank
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals
Website
www.savarapharma.com
Company Stage
Mature
Total Amount Raised
Subscriber access only
Savara, Inc. - timeline of key events
Savara, Inc. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | 128,000 | - | - | - | 257,000 | 3,000,000 | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | (100.0%) | - | - | - | 1067.3% | - | - | - | - |
| EBITDA (USD) | (13,348,163) | (15,516,115) | (21,499,684) | (29,194,000) | (39,042,000) | (35,348,000) | (29,192,000) | (69,051,000) | (77,433,000) | (48,100,000) | (36,246,000) | (38,263,000) | - | - | - |
| Operating Income (USD) | (13,396,885) | (15,628,002) | (21,539,201) | (29,279,000) | (39,373,000) | (36,456,000) | (29,956,000) | (70,045,000) | (79,025,000) | (49,300,000) | (41,477,000) | (38,839,000) | - | - | - |
| Operating Margin | - | - | - | - | - | (28481.3%) | - | - | - | (19182.9%) | (1382.6%) | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | (27615.6%) | - | - | - | (18716.0%) | (1208.2%) | - | - | - | - |
| NET Income (USD) | (13,259,931) | (15,559,489) | (21,480,285) | (28,702,000) | (39,842,000) | (36,100,000) | (29,797,000) | (61,516,000) | (78,173,000) | (49,615,000) | (43,014,000) | (38,150,000) | - | - | - |
| % Net Margin | - | - | - | - | - | (28203.1%) | - | - | - | (19305.4%) | (1433.8%) | - | - | - | - |
Savara, Inc. - employee data
Savara, Inc. - key contacts
| Name | Position | Start Date | End Date | Vcard | Bio | ||
|---|---|---|---|---|---|---|---|
| Board Member | BM |
BM Board Member
Want to see more?
Request a demo for full access to this profile
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.